Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15492372 | 0.81 | ALDH1A1 (0.52) | GRIN2BRORCALDH1A1CNR2 | |
| SCHEMBL12398796 | 0.79 | ALDH1A1 (0.35) | RORCALDH1A1CNR2FAAHMEN1 | |
| SCHEMBL11890358 | 0.79 | CNR1 (0.40) | RORCALDH1A1CNR2FAAHMEN1 | |
| SCHEMBL22900016 | 0.79 | ALDH1A1 (0.39) | GRIN2BRORCALDH1A1FAAHMEN1 | |
| SCHEMBL13195583 | 0.77 | GRIN2B (0.39) | GRIN2BALDH1A1CNR2 | |
| SCHEMBL22900010 | 0.77 | ALDH1A1 (0.38) | RORCALDH1A1CNR2FAAHMEN1 | |
| SCHEMBL22900034 | 0.76 | ALDH1A1 (0.41) | GRIN2BRORCALDH1A1FAAHMEN1 | |
| SCHEMBL14970391 | 0.76 | SMN1; SMN2 (0.50) | GRIN2BCNR2MEN1CYP1A2CYP3A4 | |
| SCHEMBL22900011 | 0.76 | ALDH1A1 (0.37) | RORCALDH1A1FAAHMEN1CYP1A2 | |
| SCHEMBL22900051 | 0.76 | ALDH1A1 (0.37) | RORCALDH1A1CNR2FAAHMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151006-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| US-20210017168-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151006-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR | GRIN2B, GRIN2A, GRIN3A | GRIN2B 1/4885RORC 307/4885ALDH1A1 2278/4885 |
| US-20210017168-A1 | SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN3A | GRIN2B 1/4885RORC 343/4885ALDH1A1 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.